Associated Genetic Biomarkers
NCI Definition: A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO) 
There is 1 clinical trial for anaplastic ganglioglioma, of which 1 is open and 0 are completed or closed. Of the trial that contains anaplastic ganglioglioma as an inclusion criterion, 1 is phase 2 (1 open).
BRAF is the most frequent gene inclusion criterion for anaplastic ganglioglioma clinical trials .
Dabrafenib, radiation therapy, and trametinib are the most common interventions in anaplastic ganglioglioma clinical trials.
Significant Genes in Anaplastic Ganglioglioma
BRAF is an inclusion eligibility criterion in 1 clinical trial for anaplastic ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and anaplastic ganglioglioma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.